Sana Biotechnology, Inc. (SANA)
| Market Cap | 384.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -266.76M |
| Shares Out | 225.02M |
| EPS (ttm) | -1.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,726,615 |
| Open | 1.820 |
| Previous Close | 1.845 |
| Day's Range | 1.675 - 1.840 |
| 52-Week Range | 1.520 - 10.500 |
| Beta | 1.64 |
| Analysts | Strong Buy |
| Price Target | 9.50 (+455.56%) |
| Earnings Date | Mar 17, 2025 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell ther... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for SANA stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 455.56% from the latest price.
News
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options If you suffer...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during th...
Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421
SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which als...
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transpla...
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells...
Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why
On Tuesday, Sana Biotechnology Inc SANA released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) t...
This Biotech Stock Just Soared 240%. Why It Can Go Higher.
The shares are at about $5 now, and strategists see a chance they could go to $10.
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression
Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, address...
Sana Biotechnology to Present at December 2024 Investor Conferences
SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology: The Story Becomes Murkier
Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended ...
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for ...
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webc...
Sana Biotechnology to Present at September 2024 Investor Conferences
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of...
Sana Biotechnology cuts the ribbon at new manufacturing facility near Seattle
Sana Biotechnology celebrated the beginning of a new chapter on its journey to make drugs that treat complicated diseases, cutting the ribbon outside the company's new manufacturing facility in Bothel...
Sana Biotechnology to Present at May and June 2024 Investor Conferences
SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas...
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent...
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence withou...